# **Special Issue**

# Targeted Alpha Therapy (TAT): Progress in Radionuclide Production, Radiochemistry and Applications

## Message from the Guest Editors

In addition to imaging purposes, nuclear medicine offers promising therapeutic options based on the specific irradiation of malignant cells. This application is illustrated by the general concept of targeted radionuclide therapy (TRT) and applied by the use of radiopharmaceuticals which favor radionuclides able to transmit high energy to matter but with low penetration. Among all the existing \( \bigsilon \)-emitters, only few have suitable properties for potential clinical application. Although accessibility issues have hampered the development of radiopharmaceuticals for targeted alpha therapy (TAT), the better general knowledge acquired over the past few years has made \( \Bar{\text{\subset}}\)-emitters increasingly attractive. It is in this context that this Special Issue of *Pharmaceuticals* will be published, the main idea being to gather contributions in the form of research papers, short communications or review articles discussing radionuclides for TAT and covering production processes, radiochemistry or potential

### **Guest Editors**

Dr. Jean-François Gestin

Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000 Nantes, France

applications (preclinical, clinical and industrial).

### Dr. Romain Eychenne

- 1. Groupement d'Intérêt Public ARRONAX, 1 Rue Aronnax, F-44817 Saint-Herblain, France
- 2. Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000 Nantes, France

### Deadline for manuscript submissions

closed (29 September 2023)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



### mdpi.com/si/117684

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

